Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-18T10:12:30.047Z Has data issue: false hasContentIssue false
  • English
  • Français

Debits and Credits in the Management of Depression

Published online by Cambridge University Press:  06 August 2018

John A. Henry
John A. Henry*
Affiliation:
National Poisons Unit, Guy's Hospital, London SE1 9RT
Get access Rights & Permissions [Opens in a new window]

Abstract

Concern over the cost of health care is playing an increasing role in Great Britain, but evaluation of benefit is generally inadequate. This is particularly true in the case of depression, for which the cost of drugs is 1.9% of the National Health Service pharmaceutical budget. Since differences in effectiveness between antidepressant drugs are difficult to demonstrate, quality-of-life studies may help to identify outcome differences. At present, the worst outcome of depressive illness - suicide - absolves carers from further costs. An assessment is needed which takes into account both the direct and indirect costs of depression; this should include the costs of investment into improving diagnosis. Even without financial analyses, it is clear that some cases of suicide can be prevented by prescribing less toxic drugs, but research is needed to investigate whether use of these drugs also reduces the costs of overdose.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 163 , Issue S20: The Economic Evaluation of Antidepressant Drug Therapy , July 1993 , pp. 33 - 39
Copyright
Copyright © 1993 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

ABPI (1992) Pharma Facts and Figures. London: ABPI. Andrews, G., Hall, W., Goldstein, G., et al (1985) The economic costs of schizophrenia. Archives of General Psychiatry, 42, 537–543.Google Scholar
Babigian, H. M. & Guttmacher, L. B. (1984) Epidemiologic considerations in electroconvulsive therapy. Archives of General Psychiatry, 41, 246–253.CrossRefGoogle ScholarPubMed
Beaumont, G. (1989) The toxicity of antidepressants. British Journal of Psychiatry, 154, 454–458.Google Scholar
Black, D. (1991) Black looks … at prevention and cure. Journal of the Royal College of Physicians of London, 26(1), 9–10.Google Scholar
Black, D. A. K. & Pole, J. D. (1975) Priorities in biomedical research. Indices of burden. British Journal of Preventative Medicine, 29(4), 222–227.Google Scholar
Blacker, C. V. & Clare, A. W. (1987) Depressive disorder in primary care. British Journal of Psychiatry, 150, 737–751.Google Scholar
Calman, K. (1991) On the State of the Public Health. London: HMSO.Google Scholar
Cooper, B. S. & Rice, D. P. (1976) The economic cost of illness revisited. Social Security Bulletin, 39, 21–36.Google Scholar
Croft-Jeffreys, C. & Wilkinson, G. (1989) Estimated costs of neurotic disorder in UK general practice 1985. Psychological Medicine, 19, 549–558.Google Scholar
Croog, S. H., Levine, S., Testa, M. A., et al (1986) The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine, 314, 1657–1664.CrossRefGoogle Scholar
Doogan, D. P. (1991) Toleration and safety of sertraline: experience worldwide. In Depression - A Once in a Lifetime Event? (ed. Ashcroft, G. W.). Oxford: Clinical Neuroscience Publishers.Google Scholar
Dyer, C. (1989) Legal battle over mianserin. British Medical Journal, 298, 479.Google Scholar
Editorial (1992a) Depression and suicide: are they preventable? Lancet, 340, 700–701.CrossRefGoogle Scholar
Editorial (1992b) Discounting health care: only a matter of timing? Lancet, 340, 148–149.CrossRefGoogle Scholar
Eisenberg, J. M., Glick, H. & Koffer, H. (1989) Pharmacoeconomics: economic evaluation of pharmaceuticals. In Pharmacoepidemiology (ed. Strom, B. L.). New York: Churchill Livingstone.Google Scholar
Evans, R. W. (1991) Quality of life (letter). Lancet, 338, 636.Google Scholar
Feighner, J. P. (1991) A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. In Depression - A Once in a Lifetime Event? (ed. Ashcroft, G. W.). Oxford: Clinical Neuroscience Publishers.Google Scholar
Gerner, R., Estabrook, W., Steuer, J., et al (1980) Treatment of geriatric depression with trazodone, imipramine and placebo: a double-blind study. Journal of Clinical Psychiatry, 41, 216–220.Google Scholar
Glassman, A. H. & Bigger, J. T. (1981) Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Archives of General Psychiatry, 38, 815–820.CrossRefGoogle ScholarPubMed
Goldstein, R. B., Black, D. W., Nasrallah, A., et al (1991) The prediction of suicide: sensitivity, specificity, and predictive value of a multivariate model applied to suicide among 1906 patients with affective disorders. Archives of General Psychiatry, 48, 418–422.Google Scholar
Goodwin, G. M. (1992) The effects of treatment on mortality in affective illness. Journal of Psychopharmacology, 6, 312–317.Google Scholar
Guze, S. B. & Robins, E. (1970) Suicide among primary affective disorders. British Journal of Psychiatry, 117, 437–438.Google Scholar
Hartunian, N. S., Smart, C. N. & Thompson, M. S. (1980) The Incidence and Economic Costs of Major Health Impairments. Lexington: Lexington Books.Google Scholar
Hawton, K. (1987) Assessment of suicide risk. British Journal of Psychiatry, 150, 145–153.Google Scholar
Hertzman, P. (1983) The economic costs of mental illness in Sweden 1975. Acta Psychiatrica Scandinavica, 68, 359–367.CrossRefGoogle ScholarPubMed
Jablensky, A. (1987) Prediction of the course and outcome of depression. Psychological Medicine, 17, 1–9.Google Scholar
Jachuck, S. J., Brierley, H., Jachuck, S., et al (1982) The effect of hypotensive drugs on the quality of life. Journal of the Royal College of General Practitioners, 32, 103–104.Google Scholar
Johnson, D. A. W. (1986) Non-compliance with antidepressant therapy - an underestimated problem. Internal Medicine (suppl. 11), 14–17.Google Scholar
Johnson, F. N. (1992) The evolution of lithium therapy. Journal of Psychopharmacology, 6, 325–329.Google Scholar
Katon, W. & Roy-Byrne, P. P. (1988) Antidepressants in the medically ill: diagnosis and treatment in primary care. Clinical Chemistry, 34(5), 829–836.Google Scholar
Katon, W., von Korff, M., Lin, E., et al (1992) Adequacy and duration of antidepressant treatment in primary care. Medical Care, 30, 67–76.CrossRefGoogle ScholarPubMed
Kellerman, A. L., Rivara, F. P., Somes, G., et al (1992) Suicide in the home in relation to gun ownership. New England Journal of Medicine, 327, 467–472.Google Scholar
King, E. & Barraclough, B. (1990) Violent death and mental illness: a study of a single catchment area over eight years. British Journal of Psychiatry, 156, 714–720.CrossRefGoogle ScholarPubMed
Kreitman, N. (1982) How useful is the prediction of suicide following parasuicide? In New Trends in Suicide Prevention (eds Wilmotte, J. & Mendlewicz, J.). Basel: Karger.Google Scholar
Lapierre, Y. D. (1991) Controlling acute episodes of depression. In Depression - A Once in a Lifetime Event? (ed. G. W. Ashcroft). Oxford: Clinical Neuroscience Publishers.Google Scholar
McCoombs, J. S., Nichol, M. B., Stimmel, G. L., et al (1990) The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. Journal of Clinical Psychiatry, 51 (suppl.), 60–72.Google Scholar
McNamee, J. E. & Offord, D. R. (1990) Prevention of suicide. Canadian Medical Association Journal, 142, 1223–1230.Google Scholar
Motto, J. A. (1991) An integrated approach to estimating suicide risk. Suicide and Life Threatening Behaviour, 21, 74–89.Google Scholar
Murphy, G. R. E. (1975) The physician's responsibility for suicide: 1. an error of commission; and 2. errors of omission. Annals of Internal Medicine, 82, 301–309.Google Scholar
Office of Population Censuses and Surveys (1990) Series VS No 15. London: OPCS.Google Scholar
Office of Population Censuses and Surveys (1991) Series DH4, no. 16. London: OPCS. Orme, M. l'E. (1984) Antidepressants and heart disease. British Medical Journal, 289, 1–2.Google Scholar
Overall, J. E. (1984) Efficacy of nomifensine in different depressive syndromes. Journal of Clinical Psychiatry, 45, 85–88.Google Scholar
Paykel, E. S., Freeling, P. & Hollyman, J. A. (1988) Are tricyclic antidepressants useful for mild depression? A placebo controlled trial. Pharmacopsychiatry, 21, 15–18.Google Scholar
Prescott, L. F. & Highley, M. S. (1985) Drugs prescribed for self-poisoners. British Medical Journal, 290, 1633–1636.Google Scholar
Rabins, P. V., Harvis, K. & Koven, S. (1985) High fatality rates of late-life depression associated with cardiovascular disease. Journal of Affective Disorders, 9, 165–167.Google Scholar
Ropert, R. (1989) Fluoxetine versus clomipramine in major depressive disorders. International Clinical Psychopharmacology, 4 (suppl. 1), 89–95.Google Scholar
Rudorfer, M. V. & Potter, W. Z., (1989) Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs, 37, 713–738.Google Scholar
Slevin, M. L., Plant, H., Lynch, D., et al (1988) Who should measure quality of life, the doctor or the patient? British Journal of Cancer, 57, 109–112.CrossRefGoogle ScholarPubMed
Stevens, J. B. & Wilkinson, E. G. (1971) Drugs, dry mouth and dental disease. Psychosomatics, 12, 310–312.Google Scholar
Stoudemire, A., Frank, R., Hedemark, N., et al (1986) The economic burden of depression. General Hospital Psychiatry, 8, 387–394.Google Scholar
Tesar, G. E., Rosenbaum, J. F., Biederman, J., et al (1987) Orthostatic hypotension and antidepressant pharmacotherapy. Psychopharmacological Bulletin, 23, 182–186.Google Scholar
Thompson, C. & Thompson, C. M. (1989a) The prescribing of antidepressants in general practice. I: a critical review. Human Psychopharmacology, 4, 190.Google Scholar
Thompson, C. & Thompson, C. M. (1989b) The prescribing of antidepressants in general practice. II: a placebo-controlled trial of low dose dothiepin. Human Psychopharmacology, 4, 191–204.Google Scholar
Tsuang, M. T., Woolson, J. R. F. & Fleming, J. A. (1980) Premature deaths in schizophrenia and affective disorders. Archives of General Psychiatry, 37, 979–983.Google Scholar
Tyrer, P. (1978) Drug treatment of psychiatric patients in general practice. British Medical Journal, ii, 1008–1010.Google Scholar
Weisbrod, B. A. (1981) Benefit-cost analysis of a controlled experiment treating the mentally ill. Journal of Human Resources, 16, 523–548.Google Scholar
Weiss, K. B., Gergen, P. J. & Hodgson, T. A. (1992) An economic evaluation of asthma in the United States. New England Journal of Medicine, 326, 862–866.Google Scholar
Weissman, M. M. (1974) The epidemiology of suicide attempts, 1960-1971. Archives of General Psychiatry, 30, 737–746.CrossRefGoogle Scholar
Weissman, M. M., Myers, J. K. & Thompson, W. D. (1981) Depression and its treatment in a US urban community 1975-1976. Archives of General Psychiatry, 38, 417–421.Google Scholar
Winokur, G. & Tsuang, M. (1975) The Iowa 500: suicide in mania, depression, and schizophrenia. American Journal of Psychiatry, 132, 650–653.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.